Jazz Pharmaceuticals plc filings document material events for an Ireland-domiciled biopharmaceutical issuer with Nasdaq-listed ordinary shares. Recent 8-K reports furnish quarterly and annual financial results, guidance, corporate presentations and product-level commentary for Xywav, Epidiolex, Modeyso and oncology launches.
The company’s filings also record clinical and regulatory disclosures for Ziihera (zanidatamab-hrii) and the HERIZON-GEA-01 program, board and committee changes, standard director compensation and indemnification arrangements, and settlement agreements involving patent and related commercial disputes. These records tie Jazz’s capital-market disclosures to its neuroscience and oncology portfolio, governance structure and material business events.
Jazz Pharmaceuticals senior vice president of Technical Operations Mary Elizabeth Henderson reported both an equity award and a share sale. She received 4,447 ordinary shares as a restricted stock unit grant at a price of $0.00 per share under the company’s 2011 Equity Incentive Plan. These units vest in four equal annual installments starting on March 5, 2026, with one-quarter vesting each year over four years. On the same date, she sold 5,343 ordinary shares in open-market transactions at a weighted average price of $194.4852 per share, in multiple trades between $194.1900 and $194.5000. According to the filing, these shares were sold to satisfy tax obligations arising from the vesting of previously granted restricted stock units, and she held 28,728 ordinary shares directly following the sale.
Form 144 notice filed related to proposed sales of common stock for JAZZ. The filing lists reported transactions by Patricia Carr: 1,253 shares sold on 02/26/2026 for $243,810 and 4,660 shares sold on 12/05/2025 for $797,783. The filing also lists issuer performance-share entries dated 01/16/2026.
ETRADE FINANCIAL CORPORATION reported a Form 144 notice to sell 2,370 performance shares dated 02/26/2026 as compensation. The filing lists Patricia Carr in prior activity, showing a sale of 4,660 common shares on 12/05/2025.
Jazz Pharmaceuticals submitted a Form 144 notice regarding proposed issuance/sale of restricted common stock as compensation. The filing lists 10,116 restricted common shares tied to 02/26/2026 and labels the transaction type as compensation.
The filing also reports a prior sale: Mary Elizabeth Henderson sold 2,238 common shares on 12/09/2025 for $379,365. The document otherwise provides standard Form 144 disclosure items for an issuer-related restricted stock transaction.
Jazz Pharmaceuticals plc describes a rare-disease focused biopharma business built around neurology and oncology therapies, anchored by its oxybate sleep franchise and epilepsy and cancer drugs. The company emphasizes Xywav and Epidiolex/Epidyolex as its largest products, with Xywav generating $1,657.0 million and Epidiolex/Epidyolex $1,059.2 million of net product sales in 2025.
Oncology growth is led by Zepzelca, with $307.3 million of 2025 net sales, and newer launches Ziihera and Modeyso, both approved under FDA’s accelerated approval pathway for difficult-to-treat cancers. Rylaze adds another $402.9 million, and legacy Xyrem has declined to $146.0 million amid generic and authorized generic competition.
The report highlights revenue diversification away from high-sodium Xyrem, extensive global commercialization, and a deep pipeline including HER2-targeted antibody zanidatamab, additional Vyxeos studies, early-stage oncology assets JZP815 and JZP898, and expanded indications for Epidiolex. Jazz also underscores investment in R&D talent, scalable operations, and an inclusion-focused culture across roughly 2,890 employees.
Jazz Pharmaceuticals reported record 2025 total revenues of $4.27 billion, up 5%, with fourth-quarter revenue of $1.20 billion, up 10% year over year. Growth was driven by neuroscience and oncology franchises.
Flagship sleep drug Xywav generated $1.66 billion in 2025 sales, up 12%, while Epidiolex/Epidyolex reached $1.06 billion, up 9%. Oncology net product sales were $1.13 billion, up 2%, including launches of Modeyso and Ziihera.
Despite strong revenue, Jazz posted a 2025 GAAP net loss of $356 million, compared with $560 million net income in 2024, primarily due to $948 million of acquired in‑process R&D and litigation settlements. Non‑GAAP adjusted net income was $522 million. The company generated $1.36 billion of operating cash flow and guided 2026 revenue to $4.25–$4.50 billion.
Jazz Pharmaceuticals plc executive Mary Elizabeth Henderson reported an equity award vesting. On January 16, 2026, she acquired 10,116 ordinary shares of Jazz Pharmaceuticals at a stated price of $0.0 per share. These shares relate to performance share awards originally granted on March 3, 2023, with the performance-based vesting conditions certified as achieved on January 16, 2026.
Following this transaction, Henderson beneficially owns 29,624 ordinary shares in total, held directly. She serves as SVP, Technical Operations at Jazz Pharmaceuticals. The Form 4 indicates this is a non-derivative acquisition tied to prior performance awards rather than an open-market purchase.
Jazz Pharmaceuticals executive Patricia Carr, who serves as SVP and Chief Accounting Officer, reported an acquisition of company stock. On January 16, 2026, she acquired 2,370 ordinary shares at a price of $0.0 per share. These shares will be delivered under performance share awards originally granted on March 3, 2023, after the company certified that the performance-based vesting requirements were satisfied on January 16, 2026. Following this award vesting, Carr now directly beneficially owns 9,382 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals’ EVP & Chief Legal Officer Neena M. Patil reported equity compensation activity in the company’s ordinary shares. On January 16, 2026, she received 8,852 ordinary shares at $0.0 per share upon vesting of performance share awards that were originally granted on March 3, 2023, after performance goals were certified as achieved.
On the same date, 3,275 ordinary shares were disposed of at $171.16 per share, with the filing explaining these shares were withheld from the vesting and distribution of the performance awards to satisfy her tax obligations. After these transactions, she directly beneficially owned 53,339 ordinary shares of Jazz Pharmaceuticals.